NOTCH2 and neoplasm: Likewise, reduced occurrence of CSC also explained the beneficial effect proven by the combination of a cross-reactive Notch 2/3 antibody, OMP-59R5, and paclitaxel, which significantly decreased the growth of pancreatic, breast, ovarian, and SCLC xenograft tumors and delayed tumor recurrence following discontinuation of the chemotherapeutic agents [453].